GeoVax and Enesi to develop next-gen thermostable, needle-free vaccines

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Talaj)
(Image: Getty/Talaj)

Related tags: Vaccine, GeoVax, Enesi Pharma

The two companies will combine technologies to create solid-dose, needle-free vaccines for a number of infectious diseases and emergent threat pathogens.

GeoVax, a biotech company developing human vaccines, will bring its modified vaccine Ankara virus-like particle platform, which mimics a natural viral infection and typically requires only one dose, to the partnership.

While Enesi holds the rights to ImplaVax, a solid-dose formulation and needle-free device, which is used to deliver a single, solid-dose vaccine.

Together, the companies hope to develop the next generation of vaccine products. A spokesperson for Enesi told us that the combined technology “could be used to protect against, or treat, any infectious disease using antigen or DNA-based implants. The company has initiated collaborations in Shigella, Zika and Chikungunya, and emergent threat pathogens (e.g. anthrax) and peanut allergy and is looking at many others.”

One of the key advantages of any vaccine produced through the technology would be its thermostability; Farshad Guirakhoo, GeoVax’s CSO, explained in a statement why this would be beneficial: “We think there is significant scientific rationale for expecting success especially in resource constrained countries where cold chain storage is an issue.”

This is a long-term aim for the industry, as it would mean that the industry could react quicker to the outbreaks of viruses, such as Zika, that occur in low to middle-income countries and typically in rural areas. Often such areas do not have the capabilities for secure cold chain storage.

Last year​, the UK government provided funding to an alliance of industry and academic partners to reduce the time to produce vaccines and to develop thermostable vaccines.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more